{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:06:04Z","timestamp":1786964764847,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of the Review<\/jats:title>\n                <jats:p>There have been increasing reports of cardiovascular complications of androgen deprivation therapy (ADT) leading to worse outcomes among patients with prostate cancer. While this may result from the direct effects of androgen suppression in the cardiovascular systems, there are ADT-type-specific distinct cardiovascular complications suggestive of mechanisms beyond androgen-mediated. Thus, it is critical to understand the biological and clinical impact of ADT on the cardiovascular system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Gonadotropin-releasing hormone (GnRH) agonists cause increased cardiovascular events compared to GnRH antagonists. Androgen receptor antagonists are linked to an increased risk of long QT syndrome, torsades de pointes, and sudden cardiac death. Androgen synthesis inhibitors are associated with increased rates of hypertension, atrial tachyarrhythmia, and, in rare incidences, heart failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>ADT increases the risk of cardiovascular disease. The risk among ADT drugs differs and must be evaluated to develop a medically optimal plan for prostate cancer patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-023-01424-2","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T09:02:55Z","timestamp":1685955775000},"page":"965-977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice"],"prefix":"10.1007","volume":"25","author":[{"given":"Janice","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKay","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-2985","authenticated-orcid":false,"given":"June-Wha","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"1424_CR1","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","volume":"40","author":"J-R Hu","year":"2020","unstructured":"Hu J-R, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol. 2020;40:e55\u201364.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1424_CR2","doi-asserted-by":"publisher","first-page":"e000082","DOI":"10.1161\/HCG.0000000000000082","volume":"14","author":"TM Okwuosa","year":"2021","unstructured":"Okwuosa TM, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14:e000082.","journal-title":"Circ Genom Precis Med"},{"key":"1424_CR3","unstructured":"Handelsman DJ. Androgen physiology, pharmacology, use and misuse.\u00a0In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. 2020."},{"key":"1424_CR4","doi-asserted-by":"publisher","unstructured":"Barrientos G, Llanos P, Basualto-Alarc\u00f3n C, Estrada M. Androgen-regulated cardiac metabolism in aging men. Front Endocrinol. 2020;11:316. https:\/\/doi.org\/10.3389\/fendo.2020.00316.","DOI":"10.3389\/fendo.2020.00316"},{"key":"1424_CR5","doi-asserted-by":"publisher","unstructured":"Saranyutanon S, Srivastava SK, Pai S, Singh S, Singh AP. Therapies targeted to androgen receptor signaling axis in prostate cancer: progress, challenges, and hope. Cancers 2020;12:51. https:\/\/doi.org\/10.3390\/cancers12010051.","DOI":"10.3390\/cancers12010051."},{"key":"1424_CR6","unstructured":"Nassar GN, Leslie SW. Physiology, Testosterone.\u00a0In: StatPearls [Internet]. 2022."},{"key":"1424_CR7","unstructured":"Davey RA, Grossmann M. Androgen receptor structure, function and biology: from bench to bedside. Clin Biochem Rev. 2016;37(1):3\u201315."},{"key":"1424_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1557988314522642","volume":"8","author":"JJ Su","year":"2014","unstructured":"Su JJ, Park SK, Hsieh TM. The effect of testosterone on cardiovascular disease: a critical review of the literature. Am J Mens Health. 2014;8:470\u201391.","journal-title":"Am J Mens Health"},{"key":"1424_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41569-019-0211-4","volume":"16","author":"T Gagliano-Juc\u00e1","year":"2019","unstructured":"Gagliano-Juc\u00e1 T, Basaria S. Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. 2019;16:555\u201374.","journal-title":"Nat Rev Cardiol"},{"key":"1424_CR10","doi-asserted-by":"publisher","first-page":"H768","DOI":"10.1152\/ajpheart.00471.2018","volume":"316","author":"O Ayaz","year":"2019","unstructured":"Ayaz O, et al. Long-term testosterone deficiency modifies myofilament and calcium-handling proteins and promotes diastolic dysfunction in the aging mouse heart. Am J Physiol Heart Circ Physiol. 2019;316:H768\u201380.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1424_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2147\/VHRM.S173259","volume":"14","author":"DA Chistiakov","year":"2018","unstructured":"Chistiakov DA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Role of androgens in cardiovascular pathology. Vasc Health Risk Manag. 2018;14:283\u201390.","journal-title":"Vasc Health Risk Manag"},{"key":"1424_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/JOE-11-0441","volume":"213","author":"AE Campelo","year":"2012","unstructured":"Campelo AE, Cutini PH, Massheimer VL. Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol. 2012;213:77\u201387.","journal-title":"J Endocrinol"},{"key":"1424_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/sj.bjp.0707624","volume":"153","author":"S Tsang","year":"2008","unstructured":"Tsang S, Wu S, Liu J, Wong TM. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation. Br J Pharmacol. 2008;153:693\u2013709.","journal-title":"Br J Pharmacol"},{"key":"1424_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1210\/jc.2005-1664","volume":"91","author":"GD Norata","year":"2006","unstructured":"Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab. 2006;91:546\u201354.","journal-title":"J Clin Endocrinol Metab"},{"key":"1424_CR15","doi-asserted-by":"publisher","first-page":"H1382","DOI":"10.1152\/ajpheart.00424.2009","volume":"298","author":"T Pang","year":"2010","unstructured":"Pang T, Rajapurohitam V, Cook MA, Karmazyn M. Differential AMPK phosphorylation sites associated with phenylephrine vs. antihypertrophic effects of adenosine agonists in neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2010;298:H1382-90.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"1424_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4103\/aja.aja_80_20","volume":"23","author":"R Diaconu","year":"2021","unstructured":"Diaconu R, Donoiu I, Mirea O, B\u0103l\u015feanu TA. Testosterone, cardiomyopathies, and heart failure: a narrative review. Asian J Androl. 2021;23:348\u201356.","journal-title":"Asian J Androl"},{"key":"1424_CR17","doi-asserted-by":"publisher","first-page":"E449","DOI":"10.1152\/ajpendo.00054.2003","volume":"285","author":"KL Golden","year":"2003","unstructured":"Golden KL, Marsh JD, Jiang Y, Brown T, Moulden J. Gonadectomy of adult male rats reduces contractility of isolated cardiac myocytes. Am J Physiol Endocrinol Metab. 2003;285:E449\u201353.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1424_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1540-8167.2006.00698.x","volume":"18","author":"D Guo","year":"2007","unstructured":"Guo D, et al. L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. J Cardiovasc Electrophysiol. 2007;18:196\u2013203.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1424_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.sxmr.2017.10.001","volume":"6","author":"AM Traish","year":"2018","unstructured":"Traish AM. Benefits and health implications of testosterone therapy in men with testosterone deficiency. Sex Med Rev. 2018;6:86\u2013105.","journal-title":"Sex Med Rev"},{"key":"1424_CR20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1177\/1060028014539918","volume":"48","author":"J Baillargeon","year":"2014","unstructured":"Baillargeon J, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48:1138\u201344.","journal-title":"Ann Pharmacother"},{"key":"1424_CR21","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen R, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829\u201336.","journal-title":"JAMA"},{"key":"1424_CR22","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2011.07.019","volume":"58","author":"C Ohlsson","year":"2011","unstructured":"Ohlsson C, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58:1674\u201381.","journal-title":"J Am Coll Cardiol."},{"key":"1424_CR23","doi-asserted-by":"crossref","unstructured":"Corti M, Lorenzetti S, Ubaldi A, Zilli R, Marcoccia D. Endocrine disruptors and prostate cancer. Int J Mol Sci. 2022;23(3):1216.","DOI":"10.3390\/ijms23031216"},{"key":"1424_CR24","doi-asserted-by":"crossref","unstructured":"Fontana F, et al. Gonadotropin-releasing hormone receptors in prostate cancer: molecular aspects and biological functions. Int J Mol Sci. 2020;21(24):9511.","DOI":"10.3390\/ijms21249511"},{"key":"1424_CR25","doi-asserted-by":"crossref","unstructured":"Melloni C, et al. Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design. JACC Cardio Oncol. 2020;2(1):70\u201381.","DOI":"10.1016\/j.jaccao.2020.01.004"},{"key":"1424_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00228-014-1682-1","volume":"70","author":"N Eckstein","year":"2014","unstructured":"Eckstein N, Haas B. Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer. Eur J Clin Pharmacol. 2014;70:791\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"1424_CR27","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"\u2022\u2022 Shore ND, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382:2187\u201396. This phase III trial demonstrates that relugolix, an oral GnRH antagonist, reduces risk of major cardiovascular events and achieves superior testosterone suppression compared to that of leuprolide, a GnRH agonist. Provides additional insight on evaluating GnRH antagonists and agonists as treatment options for PCa patients.","journal-title":"N Engl J Med"},{"key":"1424_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354\u201373.","journal-title":"Endocr Rev"},{"key":"1424_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133:537\u201341.","journal-title":"Circulation"},{"key":"1424_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.acvd.2019.09.006","volume":"113","author":"M Bretagne","year":"2020","unstructured":"Bretagne M, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2020;113:9\u201321.","journal-title":"Arch Cardiovasc Dis"},{"key":"1424_CR31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334.","journal-title":"Ann Oncol"},{"key":"1424_CR32","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448\u201356.","journal-title":"J Clin Oncol"},{"key":"1424_CR33","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493\u2013500. https:\/\/doi.org\/10.1002\/cncr.22933.","journal-title":"Cancer."},{"key":"1424_CR34","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine GN, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation. 2010;121:833\u201340.","journal-title":"Circulation"},{"key":"1424_CR35","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","volume":"29","author":"S Punnen","year":"2011","unstructured":"Punnen S, Cooperberg MR, Sadetsky N, Carroll PR. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011;29:3510\u20136.","journal-title":"J Clin Oncol"},{"key":"1424_CR36","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00432-020-03412-6","volume":"147","author":"DK Kim","year":"2021","unstructured":"Kim DK, et al. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study. J Cancer Res Clin Oncol. 2021;147:1217\u201326.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1424_CR37","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/cncr.33486","volume":"127","author":"SS Butler","year":"2021","unstructured":"\u2022 Butler SS, et al. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: a secondary analysis of the prostate, lung, colorectal, and ovarian (PLCO) randomized controlled trial. Cancer. 2021;127:2213\u201321. This study concludes that the use of ADT in addition to RT, compared to RT alone, does not increase risk of cardiovascular mortality. Demonstrates conflicting data in the literature, necessitating continued investigation on the side effects of ADT.","journal-title":"Cancer"},{"key":"1424_CR38","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1592\/phco.28.12.1511","volume":"28","author":"PE Kintzel","year":"2008","unstructured":"Kintzel PE, Chase SL, Schultz LM, O\u2019Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008;28:1511\u201322.","journal-title":"Pharmacotherapy"},{"key":"1424_CR39","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","volume":"202","author":"D Margel","year":"2019","unstructured":"\u2022 Margel D, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202:1199\u2013208. This prospective study suggests that GnRH antagonists are associated with lower risk of cardiovascular and cerebrovascular events than GnRH agonists. However, PCa patients with preexisting cardiovascular disease may have different cardiac outcomes, emphasizing the importance of a risk-benefit analysis when initiating ADT.","journal-title":"J Urol"},{"key":"1424_CR40","doi-asserted-by":"publisher","unstructured":"Knutsson A, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE\u2212\/\u2212 mice. Sci Rep. 2016;6. https:\/\/doi.org\/10.1038\/srep26220.","DOI":"10.1038\/srep26220"},{"key":"1424_CR41","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.21873\/anticanres.11472","volume":"37","author":"G Cicero","year":"2017","unstructured":"Cicero G, DELuca R, Dorangricchia P, Dieli F. The clinical efficacy of enzalutamide in metastatic prostate cancer: prospective single-center study. Anticancer Res. 2017;37:1475\u201380.","journal-title":"Anticancer Res"},{"key":"1424_CR42","doi-asserted-by":"publisher","first-page":"e17748","DOI":"10.1097\/MD.0000000000017748","volume":"98","author":"X Zheng","year":"2019","unstructured":"Zheng X, et al. Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Medicine. 2019;98:e17748.","journal-title":"Medicine"},{"key":"1424_CR43","doi-asserted-by":"crossref","unstructured":"Bretagne M, et al. Heart\nfailure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch\nCardiovasc Dis. 2020; 113(1):9\u201321.","DOI":"10.1016\/j.acvd.2019.09.006"},{"key":"1424_CR44","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.119.040162","volume":"140","author":"J-E Salem","year":"2019","unstructured":"\u2022 Salem J-E, et al. Androgenic effects on ventricular repolarization: a translational study from the International Pharmacovigilance Database to iPSC-cardiomyocytes. Circulation. 2019;140:1070\u201380. Demonstrates that different types of ADT confer distinct side-effect profiles (eg, enzalutamide was associated with the highest rate of death, hypokalemia was most present in abiraterone). Thus, careful discussion about each ADT option is essential when determining the most appropriate treatment plan.","journal-title":"Circulation"},{"key":"1424_CR45","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/curroncol28050289","volume":"28","author":"GS Gheorghe","year":"2021","unstructured":"Gheorghe GS, Hodorogea AS, Ciobanu A, Nanea IT, Gheorghe ACD. Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer. Curr Oncol. 2021;28:3331\u201346.","journal-title":"Curr Oncol"},{"key":"1424_CR46","doi-asserted-by":"publisher","first-page":"84572","DOI":"10.18632\/oncotarget.20028","volume":"8","author":"RB Moreira","year":"2017","unstructured":"Moreira RB, et al. Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8:84572\u20138.","journal-title":"Oncotarget"},{"key":"1424_CR47","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.clgc.2019.09.020","volume":"18","author":"R Garje","year":"2020","unstructured":"Garje R, et al. Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer. Clin Genitourin Cancer. 2020;18:e157\u201366.","journal-title":"Clin Genitourin Cancer"},{"key":"1424_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/aps.2010.236","volume":"32","author":"Y-H Lin","year":"2011","unstructured":"Lin Y-H, Chen C-L, Hou C-P, Chang P-L, Tsui K-H. A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. Acta Pharmacol Sin. 2011;32:537\u201342.","journal-title":"Acta Pharmacol Sin"},{"key":"1424_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/2090598X.2019.1690270","volume":"18","author":"MA Atta","year":"2020","unstructured":"Atta MA, Elabbady A, Sameh W, Sharafeldeen M, Elsaqa M. Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer? Arab J Urol. 2020;18:9\u201313.","journal-title":"Arab J Urol"},{"key":"1424_CR50","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2016.71.4204","volume":"35","author":"D-Y Chen","year":"2017","unstructured":"Chen D-Y, et al. Risk of cardiovascular ischemic events after surgical castration and gonadotropin-releasing hormone agonist therapy for prostate cancer: a nationwide cohort study. J Clin Oncol. 2017;35:3697\u2013705.","journal-title":"J Clin Oncol"},{"key":"1424_CR51","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4103\/1008-682X.143313","volume":"17","author":"JY Teoh","year":"2015","unstructured":"Teoh JY, et al. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl. 2015;17:493\u20136.","journal-title":"Asian J Androl"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01424-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:04:14Z","timestamp":1693681454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01424-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01424-2","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"15 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}